Could Preventing Your Baby's Eczema Also Prevent a Future Food Allergy? What New Infant Research Suggests

Key Takeaways

• Preliminary results presented at the 2026 AAAAI Annual Meeting reported that an oral microbial product, STMC-103H, was associated with a 64 percent reduction in atopic dermatitis (eczema) risk in high-risk infants who received it for a full year, compared to placebo, in an early-phase clinical trial.
• The same trial reported a 77 percent reduction in physician-diagnosed food allergy among treated infants, a secondary finding given how closely eczema and food allergy are linked in early childhood.
• This research connects to the "allergic march," the well-documented pattern where eczema in infancy often precedes and predicts the development of food allergy, asthma, and hay fever later in childhood.
• These are preliminary, conference-presented figures from a single early-phase trial, not yet published in a peer-reviewed journal. Numbers from conference presentations can change once full results are published, this is not an available or approved treatment, and it does not change current infant allergy prevention guidance.

Why researchers are looking at prevention this early

One of the more consistent patterns in pediatric allergy is something called the allergic march: a child develops eczema as an infant, and that early skin inflammation is associated with a meaningfully higher chance of developing food allergy, asthma, or hay fever later in childhood. For years, the clinical focus has mostly been on managing each of these conditions as they appear. What's changed recently is a growing research interest in intervening earlier, specifically at the eczema stage, to see whether preventing or reducing that first step of the allergic march can head off what tends to follow. It's worth noting that broader reviews of probiotic and microbial supplementation for allergy prevention have so far been limited and mixed, which is part of why a single new trial, however promising, is not yet enough to change guidance.

What the new research actually found

The study design

Researchers studied STMC-103H, an oral microbial product, in infants considered high-risk for developing atopic disease, tracking outcomes over a year of treatment in a placebo-controlled trial. The primary measure was whether infants who received the product were less likely to develop atopic dermatitis by around one year, with diagnosed food allergy tracked as a secondary measure.

The results, with an important caveat

Infants who completed the full year of treatment showed an approximate 64 percent reduction in the risk of developing atopic dermatitis compared to placebo, a meaningful difference in a condition affecting a large share of young children. The food allergy finding was, if anything, more striking: treated infants had a reported 77 percent reduction in physician-diagnosed food allergy risk compared to the placebo group. Because food allergy was a secondary measure in a still-unpublished, early-phase trial, that particular figure deserves to be read with extra caution until it's confirmed in peer-reviewed, published results.

What makes this research genuinely interesting isn't just the eczema numbers, it's the food allergy finding riding alongside it. That's consistent with everything we understand about the allergic march, where the skin barrier and early immune development seem to set the stage for what comes next. But this is conference-presented data from one early-phase trial, not a published, confirmed result, and it's not something families can act on yet. It points toward a promising future direction, not a current recommendation.

— Yuliya Leviyev, NP, Allergy Asthma

What this means for families right now

This is preliminary, unpublished research from a single early-phase trial, not an available treatment or a change to current recommendations. The reported figures could shift once the full results go through peer review, and more study is needed to confirm these findings, understand long-term safety, and determine which infants would actually benefit most before anything like this becomes part of routine care. In the meantime, current, well-established guidance on infant skin care and early allergenic food introduction, which already has strong evidence behind it for reducing food allergy risk, remains the right approach for families today.

For families with a history of eczema, food allergy, asthma, or hay fever, particularly if a sibling or parent has one or more of these conditions, this is a good reason to have a conversation with an allergist about your infant's individual risk and what current, proven prevention strategies already look like, while research like this continues to develop.

When to book a visit

Consider scheduling a consultation if you have a family history of eczema, food allergy, asthma, or hay fever and want to understand your infant's risk and current prevention options, if your baby has developed early signs of eczema and you want guidance on managing it and understanding what it may mean going forward, or if you have questions about safely introducing allergenic foods based on current, evidence-based guidance.

Disclaimer: This content is educational and does not substitute for medical advice. Always consult your physician for personal medical questions.